Abstract
Objective:
To assess whether changes in maternal angiogenic factors throughout pregnancy predict the development of preeclampsia.
Study Design:
Placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 receptor (sFlt-1) were measured in 2355 women at 10, 18, 26 and 35 weeks gestation. Receiver operator characteristic analysis was used to calculate test characteristics for changes in analytes between time points. Linear mixed-effects models generated slopes of analytes throughout pregnancy, which in turn were used as predictors in adjusted logistic regression models.
Result:
Changes in analytes yielded positive predictive values of 9 to 19% and negative predictive values of 93 to 97%. Individuals with lowest quartile slopes in PlGF had sixfold greater odds (95% confidence interval (CI): 3.5, 10.2) of preeclampsia compared with individuals in the highest quartile. With respect to sFlt-1, the highest quartile had 5.1 times greater odds (95% CI: 3.1, 8.4) than the lowest quartile.
Conclusion:
Measuring the trend in PlGF and sFlt-1 across pregnancy segregates women at increased risk of preeclampsia. However, changes in these factors throughout pregnancy lack clinically useful predictive power.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wallis AB, Saftlas AF, Hsia J, Atrash HK . Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am J Hypertens 2008; 21: 521–526.
Ananth CV, Keyes KM, Wapner RJ . Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ 2013; 347: f6564.
Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP . Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One 2014; 9: e91198.
Taylor RN, de Groot CJ, Cho YK, Lim KH . Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 1998; 16: 17–31.
Powe CE, Levine RJ, Karumanchi SA . Preeclampsia a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856–2869.
Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M . Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349–9354.
Kendall RL, Thomas KA . Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709.
Yuan HT, Haig D, Karumanchi SA . Angiogenic factors in the pathogenesis of preeclampsia. Curr Top Dev Biol 2005; 71: 297–312.
Karumanchi SA, Rana S, Taylor RN. Angiogenesis and preeclampsia. In: Taylor RN, Roberts JM, Cunningham FG, Lindheimer MD (eds). Chesley’s Hypertensive Disorders in Pregnancy, 4th edn. Academic Press: Oxford, UK, 2014, pp 113–132.
Maynard SE, Min JY, Lim KH, Li J, Mondal S, Libermann TA et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707–716.
Redman CW, Sargent IL, Staff AC . Making sense of preeclampsia – two placental causes of preeclampsia? Placenta 2014; 35: S20–S25.
Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778–787.
Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV . First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1–e6.
Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK . Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266–1274.
Unal ER, Robinson CJ, Johnson DD, Chang EY . Second-trimester angiogenic factors as biomarkers for future-onset preeclampsia. Am J Obstet Gynecol 2007; 197: 211.e1–e4.
Villa PM, Hamalainen E, Maki A, Räikkönen K, Pesonen AK, Taipale P et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Children 2013; 3: 110.
Leanos-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA et al. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassay methods are predictors of preeclampsia. J Hypertens 2012; 30: 2173–2181.
Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137–142.
McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207: 407.e1–e7.
Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119: 1234–1242.
Jacobs M, Nassar N, Roberts CL, Hadfield R, Morris JM, Ashton AW . Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol 2011; 9: 77.
Myers J, Kenny L, McCowan L, Chan EH, Dekker GA, Poston L et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013; 120: 1215–1223.
Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279–287.
Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JM Jr et al. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013; 120: 1183–1191.
Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC . Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196: 239.e1–e6.
Lisonkova S, Joseph KS . Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013; 209: 544.e1–e12.
Rana S, Karumanchi SA, Lindheimer MD . Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 2014; 63: 198–202.
Fisher KA, Luger A, Spargo BH, Lindheimer MD . Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine 1981; 60: 267–276.
Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32: 189–201.
Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911–919.
Vorovich E, French B, Ky B, Goldberg L, Fang JC, Sweitzer NK et al. Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail 2014; 20: 569–576.
Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333–338.
Acknowledgements
This research was supported by an unrestricted grant from Abbott Diagnostics Division (9MZ-04-06N03).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Presented at the 61st Annual Scientific Meeting of the Society for Gynecologic Investigation (Florence, Italy, 26–29 March 2014).
Supplementary Information accompanies the paper on the Journal of Perinatology website
Supplementary information
Rights and permissions
About this article
Cite this article
Honigberg, M., Cantonwine, D., Thomas, A. et al. Analysis of changes in maternal circulating angiogenic factors throughout pregnancy for the prediction of preeclampsia. J Perinatol 36, 172–177 (2016). https://doi.org/10.1038/jp.2015.170
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2015.170
This article is cited by
-
Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis
Heart Failure Reviews (2022)
-
Early gestational profiling of oxidative stress and angiogenic growth mediators as predictive, preventive and personalised (3P) medical approach to identify suboptimal health pregnant mothers likely to develop preeclampsia
EPMA Journal (2021)
-
Urinary trace metals, maternal circulating angiogenic biomarkers, and preeclampsia: a single-contaminant and mixture-based approach
Environmental Health (2019)
-
Infant size and the association between maternal circulating angiogenic factors and preeclampsia
Journal of Perinatology (2018)
-
Immunology of hepatic diseases during pregnancy
Seminars in Immunopathology (2016)